Latest Breaking News On - Investigational cancer therapeutics - Page 9 : comparemela.com

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

United statesMegan craigRob iannoneUniversity of texas md anderson cancer centerAmerican society of clinical oncologyJazz pharmaceuticalsCancer centerInvestigational cancer therapeuticsClinical oncologyAnnual meetingBispecific antibodyBreast cancerClinical trial

Scholar Rock (SRRK) Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients

Scholar Rock (SRRK) Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diego convention centerSan diegoJay backstromSusan henryTimothy yapTranslational sciencesScholar rock incDepartment of investigational cancer therapeuticsSociety for immunotherapy of cancerUniversity of texas md anderson cancer centerScholar rockAnnual meetingChief executive officerEstablishing proofPreliminary biomarker data

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diego convention centerUnited statesSan diegoUnited kingdomJay backstromRushmie nofsingerTimothy yapSusan henryMolly macleodExchange commissionScholar rock incUniversity of texas md anderson cancer centerSociety for immunotherapy of cancerTranslational sciencesDepartment of investigational cancer therapeuticsAnnual meeting

Dr Meric-Bernstam on the Efficacy of T-DXd in HER2-Expressing Solid Tumors

Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.

United statesNellieb connallyInstitute for personalized cancer therapyUniversity of texas md anderson cancer centerDepartment of investigational cancer therapeuticsPhasei programFunda meric bernstamInvestigational cancer therapeuticsPersonalized cancer therapyBreast cancerCancer centerThe university of texas md anderson cancer centerOnclive tvSolid tumorsTrastuzumab deruxtecanThe phase 2 destiny pantumor02 trial nct04482309

Genetic mutation diminishes drug response in some cancer patients

Researchers at Mass General Brigham have discovered a key mutation that may be a driving factor in resistance to certain drugs used to treat cancer.

Dejan juricTherapies investigational cancer therapeutics programTermeer centerCancer centerBoston based mass general brighamTargeted therapiesInvestigational cancer therapeutics programMass general cancerBreast cancerIk3ca geneRug bindingTermeer centerTargeted therapiesInvestigational cancer therapeutics